SCHEMBL1733947

SCHEMBL1733947

O=C(O)C(CCC1CC1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
SLC1A3 P43003 2/20 0.36
SLC1A2 P43004 2/20 0.36
SLC1A1 P43005 2/20 0.36
METAP1 P53582 1/20 0.36
ENPEP Q07075 3/20 0.34
PLG P00747 1/20 0.34
PLAT P00750 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.33
KDM5A P29375 1/20 0.32
KDM7A Q6ZMT4 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
ANPEP P15144 2/20 0.31
CPN1 P15169 1/20 0.31
CPB2 Q96IY4 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PTGES O14684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18281714 0.90 METAP1 (0.42) MAPTSLC1A3SLC1A2SLC1A1METAP1
SCHEMBL1734364 0.90 METAP1 (0.47) SLC1A3SLC1A2SLC1A1METAP1TP53
SCHEMBL2860535 0.90 SLC1A2 (0.34) MAPTSLC1A3SLC1A2SLC1A1METAP1
SCHEMBL28014935 0.88 METAP1 (0.50) SLC1A3SLC1A2SLC1A1METAP1LMNA
SCHEMBL28315546 0.86 METAP1 (0.48) SLC1A3SLC1A2SLC1A1METAP1KDM5A
SCHEMBL28315748 0.86 METAP1 (0.48) SLC1A3SLC1A2SLC1A1METAP1KDM5A
SCHEMBL28315755 0.86 METAP1 (0.48) SLC1A3SLC1A2SLC1A1METAP1KDM5A
SCHEMBL2856842 0.81 METAP1 (0.40) SLC1A3SLC1A2SLC1A1METAP1LMNA
SCHEMBL2857511 0.81 LTB4R (0.39) SLC1A3SLC1A2SLC1A1METAP1ANPEP
SCHEMBL4410925 0.78 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896452-B1 N-FORMYL HYDROXYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-11-16 EP disclosed
US-8044199-B2 N-formyl hydroxylamines compounds VICURON HOLDINGS LLC (US) 2011-10-25 US disclosed
US-8044199-B2 N-formyl hydroxylamines compounds VICURON HOLDINGS LLC (US) 2011-10-25 US disclosed
US-8044199-B2 N-formyl hydroxylamines compounds VICURON HOLDINGS LLC (US) 2011-10-25 US disclosed
CN-101193882-B N-Formyl Hydroxylamine Compounds as PDF Inhibitors NOVARTIS AG 2011-09-07 CN disclosed
US-20100063278-A1 N-Formyl Hydroxylamines compounds NOVARTIS AG (CH) 2010-03-11 US disclosed
US-20100063278-A1 N-Formyl Hydroxylamines compounds NOVARTIS AG (CH) 2010-03-11 US disclosed
US-20100063278-A1 N-Formyl Hydroxylamines compounds NOVARTIS AG (CH) 2010-03-11 US disclosed
US-7615635-B2 N-formyl hydroxylamines NOVARTIS AG (CH) 2009-11-10 US disclosed
US-7615635-B2 N-formyl hydroxylamines NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20090062537-A1 N-Formyl Hydrozyamine Compounds LEE KWANGHO 2009-03-05 US disclosed
EP-1994027-A2 N-FORMYL HYDROXYLAMINE COMPOUNDS Novartis AG (CH) 2008-11-26 EP disclosed
US-20080161558-A1 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics VICURON HOLDINGS LLC 2008-07-03 US disclosed
US-20080161558-A1 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics VICURON HOLDINGS LLC 2008-07-03 US disclosed
US-20080161558-A1 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics VICURON HOLDINGS LLC 2008-07-03 US disclosed
CN-101193882-A N-formyl hydroxylamine compounds as PDF inhibitors NOVARTIS AG (CH) 2008-06-04 CN disclosed
EP-1896452-A2 N-FORMYL HYDROXYLAMINE COMPOUNDS Novartis Pharma AG. (CH) 2008-03-12 EP disclosed
WO-2007106670-A2 N-FORMYL HYDROXYLAMINE COMPOUNDS NOVARTIS AG (CH) 2007-09-20 WO disclosed
WO-2006127576-A2 N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS NOVARTIS AG (CH) 2006-11-30 WO disclosed
US-4327109-A INSECTICIDES SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1982-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063278-A1 N-Formyl Hydroxylamines compounds PDF, MMP2, HNMT MAPT 4218/4885SLC1A3 3131/4885SLC1A2 3161/4885
US-20090062537-A1 N-Formyl Hydrozyamine Compounds PDF, HNMT, MMP2 MAPT 3829/4885SLC1A3 2155/4885SLC1A2 2491/4885
US-20080161558-A1 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics PDF, MMP2, PEPD MAPT 4271/4885SLC1A3 2822/4885SLC1A2 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.